




Searching News Database: Ionis Pharmaceuticals
HSMN NewsFeed - 14 Feb 2024
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
HSMN NewsFeed - 29 Dec 2021
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
HSMN NewsFeed - 9 Nov 2021
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
HSMN NewsFeed - 9 Jun 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
HSMN NewsFeed - 9 Jan 2020
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy